Vagal activity-related events and glucagon-like peptide-1 receptor agonists
Abstract
Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) carry side-effects such as dizziness and nausea related to increased vagal tone. This study investigated associations between GLP-1 RA use and the risk of vagal activity-related (VAR) events.
Methods and results: Using the Danish health registers, patients with type 2 diabetes mellitus (T2DM) first-time initiated on GLP-1 RAs (exposure) or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) (active control) were identified between January 2010 and October 2022. Standardized 1-year absolute risks of VAR events (syncope, fractures, bradyarrhythmia, or cardiac device implantation) were computed to compare risk associated with GLP-1 RA and SGLT-2i initiation. Complementary analyses in patients treated for obesity were performed as well. During the study period, 50 076 and 73 138 patients with T2DM were initiated on GLP-1 RA [47% women, median age: 59 years (interquartile range {IQR}: 50–68)] or SGLT-2i [39% women, median age: 64 years (IQR: 55–72)]. Comorbidity was equally prevalent. The standardized 1-year absolute risk of syncope was 0.58% [95% confidence interval (CI): 0.51–0.66%] among patients initiated on GLP-1 RA and comparable to patients initiated on SGLT-2i [0.56% (95% CI: 0.50–0.62%)]. One-year risks of fractures, bradyarrhythmia, and cardiac device implantation were equally low and with corresponding standardized risk ratios of 0.90 (95% CI: 0.79–1.01), 0.97 (95% CI: 0.67–1.28), and 0.86 (95% CI: 0.62–1.10), respectively. No associations were found in the group treated for obesity either.
Conclusion: In nationwide cohorts of patients treated for T2DM or obesity, initiation of GLP-1 RA was not associated with an elevated risk of VAR events. Despite a proposed argumentation of vagal activity, GLP-1 RA use was not associated with an increased risk in real-life users.
Related
- Glucagon-like peptide-1 receptor agonists beyond weight loss: A paradigm shift in cardiovascular prevention
- Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework
- Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
- Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness
- Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
BibTeX
@article{alansary2026vagal,
title = {{Vagal activity-related events and glucagon-like peptide-1 receptor agonists}},
author = {Lina Al-Ansary and Sebastian Kinnberg Nielsen and Mads Hashiba Jensen and Nina Nouhravesh and Caroline Sindet-Pedersen and Gunnar Gislason and Peter Vibe Rasmussen and Morten Lamberts and Anders Holt},
journal = {European Heart Journal. Cardiovascular Pharmacotherapy},
year = {2026},
month = sep,
doi = {10.1093/ehjcvp/pvag072},
url = {https://doi.org/10.1093/ehjcvp/pvag072},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Vagal activity-related events and glucagon-like peptide-1 receptor agonists
AU - Lina Al-Ansary
AU - Sebastian Kinnberg Nielsen
AU - Mads Hashiba Jensen
AU - Nina Nouhravesh
AU - Caroline Sindet-Pedersen
AU - Gunnar Gislason
AU - Peter Vibe Rasmussen
AU - Morten Lamberts
AU - Anders Holt
PY - 2026
DA - 2026/09/08
JO - European Heart Journal. Cardiovascular Pharmacotherapy
DO - 10.1093/ehjcvp/pvag072
UR - https://doi.org/10.1093/ehjcvp/pvag072
AB - Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) carry side-effects such as dizziness and nausea related to increased vagal tone. This study investigated associations between GLP-1 RA use and the risk of vagal activity-related (VAR) events. Methods and results: Using the Danish health registers, patients with type 2 diabetes mellitus (T2DM) first-time initiated on GLP-1 RAs (exposure) or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) (active control) were identified between January 2010 and October 2022. Standardized 1-year absolute risks of VAR events (syncope, fractures, bradyarrhythmia, or cardiac device implantation) were computed to compare risk associated with GLP-1 RA and SGLT-2i initiation. Complementary analyses in patients treated for obesity were performed as well. During the study period, 50 076 and 73 138 patients with T2DM were initiated on GLP-1 RA [47% women, median age: 59 years (interquartile range {IQR}: 50–68)] or SGLT-2i [39% women, median age: 64 years (IQR: 55–72)]. Comorbidity was equally prevalent. The standardized 1-year absolute risk of syncope was 0.58% [95% confidence interval (CI): 0.51–0.66%] among patients initiated on GLP-1 RA and comparable to patients initiated on SGLT-2i [0.56% (95% CI: 0.50–0.62%)]. One-year risks of fractures, bradyarrhythmia, and cardiac device implantation were equally low and with corresponding standardized risk ratios of 0.90 (95% CI: 0.79–1.01), 0.97 (95% CI: 0.67–1.28), and 0.86 (95% CI: 0.62–1.10), respectively. No associations were found in the group treated for obesity either. Conclusion: In nationwide cohorts of patients treated for T2DM or obesity, initiation of GLP-1 RA was not associated with an elevated risk of VAR events. Despite a proposed argumentation of vagal activity, GLP-1 RA use was not associated with an increased risk in real-life users.
SN - 2055-6837
SN - 2055-6845
ER -